Hevolution Foundation

Hevolution Foundation

Hevolution Foundation was established in 2021 by royal decree. HRH Prince Mohammed bin Salman bin Abdulaziz Al-Saud serves as chairman of the board of trustees. The foundation receives its funding through a sovereign allocation that supports global research into aging biology. The foundation deploys capital through grants and equity investments in biotechnology and pharmaceuticals. It targets early-stage companies and academic programs. Confirmed holdings include Aeovian Pharmaceuticals, Rubedo Life Sciences, Vandria SA, and Nanobiosym. Activity spans the United States and Switzerland. Structures include direct ownership positions and board seats alongside co-investors such as the XPRIZE Foundation. The organization maintains a Riyadh headquarters and a Boston hub through Hevolution Foundation US. Annual grantmaking has included $101 million to the XPRIZE Healthspan competition, $21 million to the Buck Institute, and $32.3 million to Northwestern University. February 2025: Sponsored the Global Healthspan Summit in Riyadh. The foundation also holds membership in the Longevity Biotech Association. Hevolution operates under a royal decree that links sovereign capital allocation directly to a single scientific mandate. Board composition includes Yasir Al-Rumayyan of the Public Investment Fund and private-sector trustees Ronald Burkle and Lord Evgeny Lebedev. This governance model channels public resources into private biotechnology holdings without an intermediary asset manager.